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Objective: Although current obesity therapies produce some
benefits, there is a need for new strategies to treat obesity.
A novel proposal is the use of anti-idiotypic antibodies as
surrogate ligands or hormones. These anti-idiotypic anti-
bodies carry an internal motif that imitates or mimics an
epitope in the antigen (i.e., hormone or ligand). Thus, anti-
idiotypic antibodies to several ligands may mimic them in
transducing signals when binding to their receptors.
Research Methods and Procedures: We developed an anti-
idiotypic polyclonal antibody against the region of a leptin
monoclonal antibody that competitively binds leptin, mim-
icking the active site structure of leptin. To test whether our
anti-idiotype could also reproduce leptin functions, we ex-
amined food intake, body weight, and colonic temperature
in male Wistar rats (n  9) in response to intracerebroven-
tricular administration of the leptin anti-idiotype.
Results: Our leptin anti-idiotype induced a significant re-
duction in food intake coupled with an increase in body
temperature comparable to that of leptin. That is, the intra-
cerebroventricular administration of 8.0 g of leptin anti-
idiotype or 5.0 g leptin significantly increased colonic
temperature ( 1.9  0.11 °C and 1.7  0.12 °C, respec-
tively). In addition, both decreased 24-hour food intake
(26.4  2.4% and 21.9  2.2%) compared with the
control. The gain in body weight was also decreased by
acute administration of the anti-idiotype (1.4  0.28%)
and leptin (1.1  0.17%) vs. the phosphate-buffered sa-
line control (1.3  0.15%).
Discussion: These studies revealed that the leptin anti-
idiotype inhibited food intake and enhanced heat produc-
tion, mimicking leptin’s central actions.
Key words: energy balance, energy expenditure, anti-
obesity, immunotherapy, anti-idiotypic antibodies
Introduction
Obesity is the result of a chronic imbalance between
energy intake and energy expenditure and can be a function
of elevated energy intake or reduced energy metabolism or
both (1). Although current pharmacological therapies pro-
duce some benefits, new approaches to obesity treatment
need to be developed.
A novel proposal is the use or induction of anti-idiotypic
antibodies as surrogate ligands or hormones. These antibod-
ies carry an internal image of an epitope of the external
antigen (i.e., hormone or ligand) (2) and anti-idiotypic an-
tibodies have been produced to mimic hormones or ligands
in transducing signals when binding to their receptors (3).
Anti-idiotypic antibodies have been tested in therapeutic
immunizations against several autoimmune diseases and
cancer (4) and insulin-developed anti-idiotype antibodies
reproduced some of the hormone effects, such as enhancing
glucose uptake into adipocytes (5).
We developed an antibody (anti-idiotypic antibody)
against an antibody that competitively binds leptin, poten-
tially mimicking a leptin-active site (6,7). Leptin is an
adipocyte-derived peptide hormone that is secreted in pro-
portion to body fat levels (8), and by suppressing food
intake and increasing energy expenditure, leptin serves as
the mediator of an adipose tissue–brain endocrine axis for
the regulation of energy balance (9). Although exogenous
leptin administration to some obese rodent models de-
creases food intake, increases energy expenditure, and re-
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sults in a reduction in body weight (10,11), most human
obesity is accompanied by elevated leptin levels (12), sug-
gesting a peripheral resistance to leptin. There is evidence,
however, that exogenous leptin induces weight loss in some
obese subjects with elevated endogenous serum leptin con-
centrations (13), whereas a percentage (5% to 25%) of
obese humans has been found to have low to normal plasma
leptin levels (12,14,15). Leptin administration may also
help those individuals following a weight-reducing program
in which leptin levels are reduced in the process (16).
Moreover, it may also be advantageous for the small pop-
ulation of obese individuals with leptin deficiency (17),
warranting additional research into leptin’s potential role in
the treatment of human obesity.
To test whether our anti-idiotypic antibody with struc-
tural similarity to a leptin-active site could also mimic the
function of leptin, we examined food intake, body weight,
and colonic temperature in male Wistar rats in response to
intracerebroventricular (ICV) administration of the leptin
anti-idiotype.
Research Methods and Procedures
Animals
Adult male Wistar rats (n  10; 250–325 g with a mean
of 285  8) from Harlan-Teklad (Barcelona, Spain) were
individually housed in suspended metabolic cages in a tem-
perature-controlled room (23  1 °C) on a 12:12-hour
light-dark schedule (lights on at 8:00 AM). Unless otherwise
specified, rats had free access to ground rat chow (Harlan-
Teklad) and water at all times. All procedures were per-
formed according to the international and institutional
guidelines of the Animal Care and Use Committee at the
University of Navarra.
Surgery
The rats were anesthetized with 75 mg/kg of a ketamine
HCl plus 10 mg/kg xylazine and placed in a stereotaxic
instrument (Kopf Instruments, Tujunga, CA). A 24-gauge
guide cannula (316GC; Plastics One, Roanoke, VA) was
implanted into the right lateral cerebroventricle and an-
chored to the skull with three stainless steel machine screws
(Small Parts, Miami Lakes, FL) and cranioplastic cement
(Dentsply, Detrey). The stereotaxic coordinates used were:
AP, 0.8 mm, ML, 1.2 mm with respect to bregma, and
DV, 3.5 mm from the skull surface (18). A 31-gauge
stylet (316DC; Plastics One) kept the guide cannula clear
when the rat was not receiving injections. A recovery period
after surgery extended 1 week before rats were subjected to
an angiotensin II (ANG II) drinking test. ANG II (Sigma, St.
Louis, MO) was dissolved in sterile phosphate-buffered
saline  calcium (PBS) at a concentration of 20 ng/L.
An increased drinking response of at least 3 mL of water
within 20 minutes after an ICV injection of 100 ng ANG II
supported correct cannula placement. The ANG II drinking
test was repeated before each experiment and at the com-
pletion of the study a methylene blue solution was injected
into the ventricle, and the brain was extracted from the
skull. Cannula placement was confirmed by the appearance
of dye in the ventricular system.
Monoclonal Antibody Production
To raise monoclonal antibodies, adult BALB/c mice were
administered with 30 g synthetic rat leptin peptide with
amino acid sequence AFSKSCSLPQTRGLQKPESL from
the active center along with a T-cell determinant peptide
with amino acid sequence FISEAIIHVLHRS named FISEA
(19). Both peptides were dissolved in 100 L of PBS (10
mM phosphate buffer [pH 7.4], 150 mM NaCl), and ho-
mogenized with 100 L of Freund’s complete adjuvant.
Mice were boosted twice at 1-month intervals with the same
immunogen homogenized in Freund’s incomplete adjuvant.
Fifteen days after the last immunization, one mouse (se-
lected on the basis of enzyme-linked immunosorbent assay
[ELISA] results) received an intravenous injection of 30 g
leptin in 200 L PBS, and 3 days later hybridomas were
produced by fusion of NS-1 cells with spleen cells, essen-
tially as previously described (20). One monoclonal anti-
leptin antibody, termed 3H10 (IgG3) produced by hybrid-
oma culture, was selected and purified from culture harvest
by cell separation and protein A affinity chromatography.
Hybrid clones were characterized by immunoblot of whole
mouse recombinant leptin (Peprotech EC, London, UK) as
well as by an indirect ELISA coated with 0.1 g leptin/well
or 30 different leptin synthetic peptides to characterize the
specificity of antibodies. The indirect ELISA and the im-
munoglobulin class determination were performed by stan-
dard methodology.
Production of the Anti-idiotypic Antibody (anti-3H10)
Three male Wistar rats were immunized with purified
mouse monoclonal antibody 3H10. A selected rat received
five inoculations at 21-day intervals, the first in Freund’s
complete adjuvant and four additional injections in Freund’s
incomplete adjuvant. Serum was collected and IgG fraction
purified by means of affinity chromatography on a HiTrap
protein G column (Amersham Pharmacia, Barcelona,
Spain). Buffer exchange for affinity purification was made
on a PD-10 column (Amersham Pharmacia).
To demonstrate anti-Id Ab specificity, rat antiserum pre-
pared against 3H10 was tested in an ELISA in which the
antigen, in this case purified 3H10, was coating the plate.
Thus, when both leptin (1 g/well) and rat antiserum serial
double dilutions were coincubated, there was clearly a sig-
nificant binding inhibition when comparing the titer/absor-
bance observed with the antiserum alone. To neutralize
anti-isotypic and anti-allotypic antibodies present in the rat
antiserum, a 2-hour preincubation at RT with normal mouse
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serum was made just before using the antiserum in the
ELISA. Rat normal serum was used as a negative control.
Experimental Protocol
Three treatments were randomly assigned to the ICV
cannulated rats that responded positively to ANG II. The
treatments were 0 (PBS), 5.0 g leptin, and 8.0 g
anti-idiotype injected into the lateral ventricle. Each rat
randomly received one of the treatments on a given day
followed by 2 days of recovery. For the food intake study,
each treatment was given twice, rotating in a counterbal-
anced order. All injections were performed 2 hours after the
beginning of the light cycle (between 10:00 and 11:00 AM).
Food cups were removed from the rat cages at 9:00 AM. At
10:00 AM, rats were injected in the lateral ventricle with
either 4 L of sterile PBS or an equal volume of recom-
binant rat leptin (R&D Systems, Minneapolis, MN) or anti-
idiotype in PBS using an injector cannula (C316I; Plastics
One) attached by polyethylene tubing (PE-10) to a 25-L
glass Hamilton syringe. For each trial, infusate was deliv-
ered, with a CMA/100 pump (CMA/Microdialysis) at 1.0
L/min, after which the injector cannula was left in place
for an additional 1 minute to allow for diffusion away from
injection site, before being replaced by the stylet.
Body weight and food intake were measured immediately
before injection. The food cups were refilled and reweighed
22 hours later. Food spillage was weighed and the papers
lining the chamber floor were changed. Colonic temperature
was measured using a petroleum jelly covered YSI 400
series rectal probe thermocouple thermometer (Panlab S.L.,
Barcelona, Spain) inserted a standardized distance (6 cm)
until a stable temperature reading was obtained. Baseline
temperature was measured over 60 minutes before admin-
istration of experimental treatments and every 30 minutes
over 300 minutes of post-treatment. To eliminate stress-
related elevations in temperature, rats were previously ha-
bituated to the rectal probe insertion (1 week after the food
intake study).
Statistical Analyses
Data are shown as means SEM. When two means were
compared, we used the Student’s t test. Comparisons of
more than two means were analyzed by two-way ANOVA.
Fisher’s Protected Least Significance Difference test was
used for comparisons between some specific means. A
value of p  0.05 was considered statistically significant.
Results
Figure 1 summarizes the responses of ICV leptin, anti-
idiotype and PBS on food intake. PBS-treated rats con-
sumed 17.7  0.6 g food over the 22 hours after microin-
jection at 10:00 AM. Administration of 5.0 g leptin
inhibited food intake by 22% (p  0.05), whereas 8.0 g
anti-idiotype attenuated consumption by 26% (p  0.05)
compared with PBS-treated rats. The gain in body weight
(Figure 2) was also decreased by anti-idiotype (1.4%) and
leptin (1.1%) vs. the PBS control (1.3%).
The colonic temperatures of PBS-treated rats remained
between 37.4 and 37.8 °C for the 5 hours recorded after the
injection (Figure 3). The ICV administration of 8.0 g of
leptin anti-idiotype or 5.0 g leptin significantly increased
colonic temperature (1.9  0.11 °C and 1.7  0.12 °C,
respectively), which remained elevated throughout the re-
cording period. To test whether the observed effect of
anti-idiotype on colonic temperature was caused by random/
nonspecific antibody binding, we performed a control test
with a nonimmunospecific antibody. Central administration
of this antibody failed to affect colonic temperature (data
not shown).
Discussion
Antibodies directed against antigenic determinants on
another antibody’s variable domain, or idiotope, are called
anti-idiotypic antibodies. As this region forms the antigen-
binding site, in some cases these anti-idiotypic antibodies
carry an image of the original antigen (2). If the original
antigen is a hormone or ligand, in our case leptin, the
structural similarity (i.e., internal image) lends for the pos-
sibility that the anti-idiotypic antibody can also functionally
mimic the physiological properties of the ligand and bind to
cellular receptors. Immunomanipulation, therefore, repre-
sents a novel approach to disease treatment with some
animal trials yielding promising results. The use of a growth
hormone (GH) anti-idiotype promoted growth in GH-defi-
cient rats (21), whereas antibodies against adipocytes
seem to be effective in the treatment of diet-induced
obese rats (22).
Figure 1: Effects of central leptin/anti-idiotypic antibody on food
intake in male Wistar rats (n 10). Mean food intake (g) 24 hours
after ICV administration of 5.0 g leptin, 8.0 g anti-idiotype, or
PBS. Rats were used as their own controls and values are
expressed as means SEM. *, denotes significant difference from
PBS (p  0.05).
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Our results demonstrate an anti-idiotype-induced reduc-
tion in food intake coupled with an increase in heat produc-
tion comparable to the effects of leptin. Synthesized primar-
ily by adipose tissue (23), leptin is an important regulator of
appetite and energy expenditure through its feedback effects
on the brain. Released into the circulation in proportion to
body fat mass (8), leptin enters the brain and acts on
hypothalamic sites to inhibit energy intake and enhance
energy metabolism (24,25). Alterations in leptin production
or sensitivity have been suggested to play a role in the
pathogenesis of obesity (26), and exogenous leptin is highly
effective at reversing obesity in animals that lack functional
leptin (10). Although obesity in humans and in most rodent
models is usually associated with high circulating leptin
levels and peripheral leptin resistance (12,14), recent evi-
dence suggests that up to 25% of obese individuals have low
leptin levels and may benefit from leptin treatment (15). In
addition, circulating leptin levels drop after dietary manip-
ulations that result in weight loss and seem to contribute to
hunger sensations (16) and weight regain. A leptin anti-
idiotype may be useful in these circumstances in which
leptin replacement would be beneficial. Although exoge-
nous leptin could achieve the same desired effects, use of
immunotherapy could allow subjects to generate their own
leptin, requiring only occasional priming rather than daily
injections. Therefore, a potential strategy based on leptin
anti-idiotypes may prove advantageous in the maintenance
of leptin levels and prevent the rebound effect.
Although the theoretical basis for immunotherapy is well-
founded, it is important to point out that an antibody-
vaccine is no magic bullet. The therapeutic use of antibodies
as vaccines remains difficult because of the response against
the therapeutic agent. That is, antigen presentation often
results in tolerance induction to the antigens contained
within the vaccine. Although genetic engineering can be
used to reduce the immunogenicity of rodent antibodies,
even these humanized antibodies leave open the chance
for anti-globulin responses and neutralization on repeated
therapy (27).
A more realistic use of the leptin anti-idiotype may be as
a probe in both functional and biochemical studies of the
leptin receptor. The behavioral and metabolic effects after
brain administration suggest that leptin anti-idiotype can act
on neuronal networks that control feeding and energy bal-
ance. Development of new drugs in this therapeutic area
requires an enhanced understanding of the neuroanatomy
and neurophysiology underlying the various components of
the appetite regulation and energy expenditure in the brain.
The ongoing characterization of leptin neurobiology has
provided evidence for a specific, saturable transport system
for leptin to cross the blood–brain barrier and enter the
brains of rodents and humans (28). The reduced entry of
leptin into the brain may be one of the mechanisms of
resistance in those obese individuals with elevated plasma
leptin levels. Thus, the leptin anti-idiotype, serving to map
the active sites, may facilitate receptor-based studies and
provide a molecular mechanism to account for the dysfunc-
tion. In addition, because leptin is a pleitropic hormone,
anti-idiotypes may mimic individual functions, allowing for
the study of separate systems.
These studies demonstrate that the central administration
of a leptin anti-idiotypic antibody inhibited food intake and
enhanced heat production, mimicking leptin’s central ac-
tions. Obesity is an increasingly prevalent and important
health problem and although treatment is available, sus-
tained significant weight loss (5 to 10% of initial body
weight) is rare, highlighting the urgent need for effective
Figure 2: Effects of central leptin/anti-idiotypic antibody on body
weight in male Wistar rats (n  10). The percentage change in
body weight 22 hours after intracerebroventricular administration
of 5.0 g leptin, 8.0 g anti-idiotype, or PBS. Rats were used as
their own controls and values are expressed as means  SEM. *,
denotes significant difference from PBS (p  0.05).
Figure 3: Effects of central leptin/anti-idiotypic antibody on body
temperature in male Wistar rats (n 9). Mean colonic temperature
1 hour before and 5 hours after intracerebroventricular adminis-
tration of 5.0 g leptin ( ), 8.0 g anti-idiotype (E), or PBS (Œ).
Rats were used as their own controls and values are expressed
as means  SEM. *, denotes significant difference from PBS
(p  0.05).
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new approaches. Despite rapid strides toward an ideal anti-
obesity drug, additional progress is needed to incorporate
new findings in the neurobiology of energy balance into
clinical interventions. The characterization of obesity-asso-
ciated gene products has revealed new biochemical path-
ways and molecular targets for pharmacological interven-
tion. A leptin anti-idiotype may be useful as a tool in this
progress and future studies may demonstrate a benefit in
obese individuals with normal to low leptin levels as well as
those dieters wishing to prevent or diminish the rebound
effect.
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